Concerto Biosciences

Concerto Biosciences measures, maps, and harnesses the microbial world to create best-in-class therapies and products. These assets achieve real-world efficacy and durability through naturally occurring symbioses among microbes. Powering asset discovery is our intelligence platform: Our microbial community screening apparatus (kChip) generates the right data at the right scale (40M+ combinations constructed and measured so far) needed to train a generalized AI model (kAI) of microbial ecology. Our first market is skin health, where we’ve brought a live biotherapeutic candidate for eczema to the clinic (ENS-002, or “Ensemble No.2”, a trio of bacteria that counteracts S. aureus virulence) and formulated a postbiotic ferment for consumer use (CB-002). In our mission to solve diverse market pain points with microbial solutions, we are building a pipeline across dermatology, women’s health, and food science. Concerto partners with global organizations to bring our solutions to market, tapping into microbial ecology to meet 21st-century needs of people and planet.